Production (Stage)
Serina Therapeutics, Inc.
SER
$5.75
$0.01430.25%
AMEX
| 03/31/2025 | 12/31/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -200.00% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -200.00% | |||
| Cost of Revenue | 24.78% | -2.07% | |||
| Gross Profit | -24.04% | 0.92% | |||
| SG&A Expenses | 71.61% | -41.81% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | 44.32% | -23.79% | |||
| Operating Income | -43.83% | 23.32% | |||
| Income Before Tax | -75.22% | -298.99% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | -75.22% | -298.99% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -25.00% | -55.56% | |||
| Net Income | -75.66% | -294.33% | |||
| EBIT | -43.83% | 23.32% | |||
| EBITDA | -45.41% | 23.57% | |||
| EPS Basic | 16.59% | -471.25% | |||
| Normalized Basic EPS | -81.60% | -268.42% | |||
| EPS Diluted | -64.11% | -331.23% | |||
| Normalized Diluted EPS | -81.60% | -304.58% | |||
| Average Basic Shares Outstanding | -47.37% | 109.42% | |||
| Average Diluted Shares Outstanding | -47.37% | 72.41% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||